6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Common O
adverse O
reactions O
occurring O
in O
> O
=1 O
% O
in O
subjects O
treated O
with O
KERYDIN O
included O
application O
site O
exfoliation O
, O
ingrown O
toenail O
, O
application O
site O
erythema O
, O
and O
application O
site O
dermatitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Anacor O
Pharmaceuticals O
at O
1-844-4ANACOR O
[ O
1-844-426-2267 O
] O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
two O
clinical O
trials O
, O
791 O
subjects O
were O
treated O
with O
KERYDIN O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
are O
listed O
below O
( O
Table O
1 O
) O
. O

Table O
1 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=1 O
% O
of O
KERYDIN O
Topical O
Solution O
, O
5 O
% O
-Treated O
Subjects O
and O
at O
a O
Greater O
Frequency O
than O
Observed O
with O
Vehicle O
Preferred O
Term O
KERYDINN=791 O
n O
( O
% O
) O
VehicleN=395 O
n O
( O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
21 O
( O
2.7 O
% O
) O
1 O
( O
0.3 O
% O
) O
Ingrown B-OSE_Labeled_AE
toenail I-OSE_Labeled_AE
20 O
( O
2.5 O
% O
) O
1 O
( O
0.3 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
13 O
( O
1.6 O
% O
) O
0 O
( O
0 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
10 O
( O
1.3 O
% O
) O
0 O
( O
0 O
% O
) O
A O
cumulative O
irritancy O
study O
revealed O
the O
potential O
for O
KERYDIN O
to O
cause O
skin B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
. O

There O
was O
no O
evidence O
that O
KERYDIN O
causes O
contact O
sensitization O
. O

